This systematic review outlines the role of various biomarkers in understanding the pathophysiology, diagnosis, and prognosis of hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
May refine HCM biomarker selection in practice; extends synthesized evidence on pathophysiology, diagnosis, and prognosis.
The study of biomarkers and their signalling pathways has allowed the development of new therapeutic strategies in a range of disorders. The aim of the present systematic review is to provide an overview of different biomarkers in patients with hypertrophic cardiomyopathy that could give some insight into the pathophysiologic mechanism(s) underlying the typical clinical and histological manifestations of the disease. Several pathophysiological models are presented and discussed, including studies that have investigated these biomarkers for diagnostic and prognostic reasons, in relation to disease progression and/or mortality.
No takes yet. Share an insight, caveat, or question.
Cambronero et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: